Neoadjuvant Chemotherapy Clinical Trial
Official title:
To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study
The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen the invasiveness of surgical resection. The FOLFOXIRI regimen has been shown to have a high objective efficiency in advanced colorectal cancer. This phase II trial is to explore the pathological remission rate and safety of stage II/III locally advanced colon cancer with high risk of recurrence to FOLFOXIRI regimen of neoadjuvant chemotherapy alone.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Active, not recruiting |
NCT03719833 -
Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
|
||
| Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
| Not yet recruiting |
NCT04384601 -
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
|
Phase 3 | |
| Recruiting |
NCT04576143 -
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
| Recruiting |
NCT03493880 -
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
|
||
| Completed |
NCT06149884 -
Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
|
||
| Recruiting |
NCT03715686 -
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes
|
N/A | |
| Recruiting |
NCT03750669 -
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05522985 -
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT03349177 -
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
|
Phase 2/Phase 3 | |
| Terminated |
NCT03585062 -
Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT06120309 -
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
|
||
| Recruiting |
NCT04004559 -
MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
|
||
| Recruiting |
NCT04047693 -
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06220214 -
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05910710 -
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
|
||
| Suspended |
NCT05503108 -
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05367206 -
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
|
Phase 3 |